Compare PAHC & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAHC | GLUE |
|---|---|---|
| Founded | 1946 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2014 | 2021 |
| Metric | PAHC | GLUE |
|---|---|---|
| Price | $34.29 | $15.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $41.25 | $32.00 |
| AVG Volume (30 Days) | 226.7K | ★ 1.5M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | ★ 1883.33 | N/A |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $833,350,000.00 | $123,672,000.00 |
| Revenue This Year | $17.03 | N/A |
| Revenue Next Year | $3.82 | $2.45 |
| P/E Ratio | ★ $18.68 | $72.42 |
| Revenue Growth | 4.12 | ★ 63.54 |
| 52 Week Low | $27.83 | $4.15 |
| 52 Week High | $60.08 | $25.77 |
| Indicator | PAHC | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 54.27 | 30.37 |
| Support Level | $30.55 | $14.77 |
| Resistance Level | $37.92 | $17.99 |
| Average True Range (ATR) | 1.26 | 1.36 |
| MACD | 0.15 | -1.00 |
| Stochastic Oscillator | 56.00 | 8.16 |
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).